{
    "2018-02-01": [
        [
            {
                "time": "2018-03-01",
                "original_text": "Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.",
                "features": {
                    "keywords": [
                        "Novartis",
                        "tender offer",
                        "Advanced Accelerator Applications"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer",
                "features": {
                    "keywords": [
                        "Advanced Accelerator Applications",
                        "Novartis",
                        "Tender Offer"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Novartis Closes Subsequent Offering Period Of Tender Offer For AAAP",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AAAP",
                        "Tender Offer"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Commentary: How We Can Bring Health Care to the World’s Underserved",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Underserved"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Analyzing Celgene’s Performance in 4Q17",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Performance",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa",
                "features": {
                    "keywords": [
                        "Roche",
                        "Sales",
                        "Tecentriq",
                        "Alecensa"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "GSK Projects Modest Long-Term Revenue Growth for Vaccines Portfolio",
                "features": {
                    "keywords": [
                        "GSK",
                        "Revenue Growth",
                        "Vaccines"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "The Swiss Stock Market Fell On Pharma Weakness",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Pharma Weakness"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Stada Names Sandoz Manager as Fifth CEO Since 2016",
                "features": {
                    "keywords": [
                        "Stada",
                        "Sandoz",
                        "CEO"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}